Unlearn, an 8VC investment, has developed the first machine learning platform for creating Intelligent Control Arms with Digital Twins, allowing drug developers to dramatically improve clinical evidence and trial power, while lowering the risk of trial failure, thereby increasing confidence in clinical trial results.
In late 2020, Occam recruited Ann Taylor, MD to the Board of Unlearn. Ann brings with her deep experience in clinical development, having served as CMO for AstraZeneca until 2021.
